Interestingly, ibrutinib or acalabrutinib prevents allergen-IgE-mediated bronchoconstriction in isolated human lung tissues ex vivo and acalabrutinib effectively protects against IgE-mediated systemic anaphylaxis and death in a humanized mouse model in vivo, suggesting an almost complete blockade of histamine and leukotriene release by mast cells and basophils (Dispenza et al., 2020). The gene discussed is IGHE; the disease is anaphylaxis.